Sveriges Riksbank
Bid date, 2021-01-21 | |
Bid Date | 2021-01-21 |
Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
Offerent Amount | USD 10 billion |
Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
Settlement Date | 2021-01-25 |
Minimum Permitted Bid Volume | 100 USD million per bid |
Maximum Allocation | 40 per cent of the Offerend amount |
Allocation time | Not later than 15.00 (CET/CEST) on the Bid date |
Maturity Date | 2021-04-19 |
Maximum Number of Bids | 10 per individual institution |
Minimum bid rate | 0.33 % |
Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-01-19
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Wolters Kluwer N.V.19.9.2025 08:00:00 CEST | Press release
Wolters Kluwer completes capital reduction
Orion Oyj19.9.2025 08:00:00 CEST | Press release
80,802 Orion Corporation A shares converted into B shares
JDE Peet's N.V.19.9.2025 07:55:00 CEST | Press release
Update on intended recommended public offer by KDP for JDE Peet's
Sampo plc19.9.2025 07:30:00 CEST | Press release
Sampo plc’s share buybacks 18 September 2025
Idorsia Pharmaceuticals Ltd19.9.2025 07:00:00 CEST | Press release
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom